Clinical presentation and outcome of nonfunctional pancreatic neuroendocrine tumors in a modern cohort

被引:5
作者
Watley, Duncan C. [1 ]
Ly, Quan P. [1 ,3 ]
Talmon, Geoffrey [2 ,3 ]
Are, Chandrakanth [1 ,3 ]
Sasson, Aaron R. [1 ,3 ]
机构
[1] Univ Nebraska Med Ctr, Dept Surg, Div Surg Oncol, Omaha, NE 68198 USA
[2] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA
[3] Fred & Pamela Buffet Canc Ctr, Omaha, NE USA
关键词
Pancreatic tumor; Nonfunctional pancreatic tumors; Incidental tumors; Incidental nonfunctional pancreatic tumor; Neuroendocrine tumor; Nonfunctional neuroendocrine tumor; ENDOCRINE TUMORS; PROGNOSTIC-FACTORS; FEATURES;
D O I
10.1016/j.amjsurg.2015.08.012
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: The natural history of nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) is largely unstudied due to its rarity. The primary goal of this study was to characterize clinical features and outcomes of incidental NF-PNETs. METHODS: An institutional review board-approved retrospective study of patients with NF-PNET evaluated by the Surgical Oncology of University of Nebraska Medical Center was performed. Patients were evaluated with dedicated pancreatic and liver imaging using multiphasic computed tomographic scan and dedicated magnetic resonance imaging protocols. RESULTS: Forty-six patients (male, 47.8%) were evaluated, and 35 ultimately resected. Of these, 16 tumors were discovered incidentally. The median age was 62 and 59 years in incidental and symptomatically discovered, respectively. Incidental median size was 2.4 cm vs 6 cm in the symptomatic group, with a P value of.037. The presence of lymphatic and liver metastases was 10% and 25% incidental and 45% and 67% for those with symptoms (lymphatic involvement, P = .05; liver metastases P = .07). Median overall survival was 45 and 76 months (P = .03). CONCLUSIONS: Incidentally discovered NF-PNETs represent a malignancy with more questions than answers. Our series indicates that these cancers are more indolent than previously believed. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:1192 / 1195
页数:4
相关论文
共 50 条
  • [41] Outcome of surgery for ileojejunal neuroendocrine tumors
    Habbe, Nils
    Fendrich, Volker
    Heverhagen, Anna
    Ramaswamy, Annette
    Bartsch, Detlef K.
    SURGERY TODAY, 2013, 43 (10) : 1168 - 1174
  • [42] Long-Term Outcome of Laparoscopic Surgery for Pancreatic Neuroendocrine Tumors
    Haugvik, Sven-Petter
    Marangos, Irina Pavlik
    Rosok, Bard Ingvald
    Pomianowska, Ewa
    Gladhaug, Ivar Prydz
    Mathisen, Oystein
    Edwin, Bjorn
    WORLD JOURNAL OF SURGERY, 2013, 37 (03) : 582 - 590
  • [43] Neuroendocrine Tumors of Midgut and Hindgut Origin: Tumor-Node-Metastasis Classification Determines Clinical Outcome
    Jann, Henning
    Roll, Stephanie
    Couvelard, Anne
    Hentic, Olivia
    Pavel, Marianne
    Mueller-Nordhorn, Jacqueline
    Koch, Martin
    Roecken, Christoph
    Rindi, Guido
    Ruszniewski, Philippe
    Wiedenmann, Bertram
    Pape, Ulrich-Frank
    CANCER, 2011, 117 (15) : 3332 - 3341
  • [44] Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study
    Sallinen, Ville J.
    Le Large, Tessa T. Y.
    Tieftrunk, Elke
    Galeev, Shamil
    Kovalenko, Zahar
    Haugvik, Sven-Petter
    Antila, Anne
    Franklin, Oskar
    Martinez-Moneo, Emma
    Robinson, Stuart M.
    Panzuto, Francesco
    Regenet, Nicolas
    Muffatti, Francesca
    Partelli, Stefano
    Wiese, Dominik
    Ruszniewski, Philippe
    Dousset, Bertrand
    Edwin, Bjorn
    Bartsch, Detlef K.
    Sauvanet, Alain
    Massimo, Falconi
    Ceyhan, Gueralp O.
    Gaujoux, Sebastien
    HPB, 2018, 20 (03) : 251 - 259
  • [45] Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenarios
    Konstantinoff, Katerina S.
    Morani, Ajaykumar C.
    Hope, Thomas A.
    Bhosale, Priya R.
    Francis, Isaac R.
    Yano, Motoyo
    Iravani, Amir
    Trikalinos, Nikolaos A.
    Itani, Malak
    ABDOMINAL RADIOLOGY, 2023, 48 (05) : 1843 - 1853
  • [46] Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors
    Pulvirenti, Alessandra
    Rao, Deepthi
    Mcintyre, Caitlin A.
    Gonen, Mithat
    Tang, Laura H.
    Klimstra, David S.
    Fleisher, Martin
    Ramanathan, Lakshmi V.
    Reidy-Lagunes, Diane
    Allen, Peter J.
    HPB, 2019, 21 (05) : 612 - 618
  • [47] A Tale of Two Tumors: Treating Pancreatic and Extrapancreatic Neuroendocrine Tumors
    Halperin, Daniel M.
    Kulke, Matthew H.
    Yao, James C.
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 1 - 16
  • [48] Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance
    Bezzi, C.
    Mapelli, P.
    Presotto, L.
    Neri, I
    Scifo, P.
    Savi, A.
    Bettinardi, V
    Partelli, S.
    Gianolli, L.
    Falconi, M.
    Picchio, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (12) : 4002 - 4015
  • [49] Therapy innovation for the treatment of pancreatic neuroendocrine tumors
    Riccardi, Ferdinando
    Rizzo, Mimma
    Festino, Lucia
    Ambrosio, Francesca
    Molino, Carlo
    Uomo, Generoso
    Carteni, Giacomo
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 : S91 - S102
  • [50] Pancreatic neuroendocrine tumors: Pathologic and molecular characteristics
    Shi, Chanjuan
    Klimstra, David S.
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2014, 31 (06) : 498 - 511